Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.

Assi HA, Mukherjee S, Kunz PL, Machiorlatti M, Vesely S, Pareek V, Hatoum H.

Oncologist. 2020 Feb;25(2):e276-e283. doi: 10.1634/theoncologist.2019-0466. Epub 2019 Oct 2.

2.

Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer Database.

Assi HA, Mukherjee S, Machiorlatti M, Vesely S, Pareek V, Hatoum H.

Anticancer Res. 2020 Feb;40(2):847-855. doi: 10.21873/anticanres.14017.

PMID:
32014928
3.

Socio-Demographic Disparities in Gastric Adenocarcinoma: A Population-Based Study.

Rana N, Gosain R, Lemini R, Wang C, Gabriel E, Mohammed T, Siromoni B, Mukherjee S.

Cancers (Basel). 2020 Jan 9;12(1). pii: E157. doi: 10.3390/cancers12010157.

4.

Role of Adjuvant Chemotherapy in Pulmonary Carcinoids: An NCDB Analysis.

Gosain R, Groman A, Yendamuri SS, Iyer R, Mukherjee S.

Anticancer Res. 2019 Dec;39(12):6835-6842. doi: 10.21873/anticanres.13900.

PMID:
31810950
5.

Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Mukherjee S, Fountzilas C, Boland PM, Gosain R, Attwood K, Tan W, Khushalani N, Iyer R.

Target Oncol. 2020 Feb;15(1):85-92. doi: 10.1007/s11523-019-00692-y.

PMID:
31802410
6.

Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study.

Gosain R, Ball S, Rana N, Groman A, Gage-Bouchard E, Dasari A, Mukherjee S.

Cancer. 2020 Feb 15;126(4):792-799. doi: 10.1002/cncr.32607. Epub 2019 Nov 12.

PMID:
31714595
7.

Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.

Assi HA, Mukherjee S, Kunz PL, Machiorlatti M, Vesely S, Pareek V, Hatoum H.

Oncologist. 2019 Oct 2. pii: theoncologist.2019-0466. doi: 10.1634/theoncologist.2019-0466. [Epub ahead of print]

8.

Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial with Predictive Molecular Correlates.

Malhotra U, Mukherjee S, Fountzilas C, Boland P, Miller A, Patnaik S, Attwood K, Yendamuri S, Adjei A, Kannisto E, Opyrchal M, Bushunow P, Loud P, Iyer R, Khushalani N.

Mol Cancer Ther. 2020 Jan;19(1):304-311. doi: 10.1158/1535-7163.MCT-19-0240. Epub 2019 Oct 1.

PMID:
31575653
9.

Interleukin-6 as a biomarker in patients with hepatobiliary cancers.

Gosain R, Anwar S, Miller A, Iyer R, Mukherjee S.

J Gastrointest Oncol. 2019 Jun;10(3):537-545. doi: 10.21037/jgo.2019.01.09.

10.

Pembrolizumab in advanced gastric cancer: pioneering or prosaic?

Mukherjee S, Hochwald SN.

Ann Transl Med. 2019 Mar;7(Suppl 1):S3. doi: 10.21037/atm.2019.01.17. No abstract available.

11.

Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines.

Gosain R, Mukherjee S, Yendamuri SS, Iyer R.

Cancers (Basel). 2018 Dec 12;10(12). pii: E510. doi: 10.3390/cancers10120510. Review.

12.

Spontaneous Regression of Metastatic Pancreatic Cancer: A Role for Recurrent Inflammation.

Ibrahimi S, Mukherjee S, Alhyari L, Rubin E, Aljumaily R.

Pancreas. 2019 Jan;48(1):e4-e6. doi: 10.1097/MPA.0000000000001193. No abstract available.

PMID:
30531247
13.

Woodchuck VEGF (wVEGF) characteristics: Model for angiogenesis and human hepatocellular carcinoma directed therapies.

Huang H, Salavaggione O, Rivera L, Mukherjee S, Brekken R, Tennant B, Iyer R, Adjei A.

Arch Biochem Biophys. 2019 Jan;661:97-106. doi: 10.1016/j.abb.2018.11.008. Epub 2018 Nov 13.

PMID:
30439360
14.

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.

Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, Grossenbacher SK, Withers SS, Rebhun RB, Hartigan-O'Connor DJ, Méndez-Lagares G, Tarantal AF, Isseroff RR, Griffith TS, Schalper KA, Merleev A, Saha A, Maverakis E, Kelly K, Aljumaily R, Ibrahimi S, Mukherjee S, Machiorlatti M, Vesely SK, Longo DL, Blazar BR, Canter RJ, Murphy WJ, Monjazeb AM.

Nat Med. 2019 Jan;25(1):141-151. doi: 10.1038/s41591-018-0221-5. Epub 2018 Nov 12.

15.

Degloving the Feet: A Severe Case of Hand-Foot Syndrome After Induction Chemotherapy.

Kasht R, Mukherjee S, Ibrahimi S.

J Cutan Med Surg. 2018 Nov/Dec;22(6):609. doi: 10.1177/1203475418775379. No abstract available.

PMID:
30322303
16.

Granulocytic sarcoma and mediastinal germ cell tumor: A common cell of origin?

Mukherjee S, Ibrahimi S, Scordino T, Cherry M.

Hematol Oncol Stem Cell Ther. 2019 Dec;12(4):228-229. doi: 10.1016/j.hemonc.2018.05.004. Epub 2018 Jun 15. No abstract available.

17.

Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: A population-based study.

Samuel S, Mukherjee S, Ammannagari N, Pokuri VK, Kuvshinoff B, Groman A, LeVea CM, Iyer R.

PLoS One. 2018 Jun 11;13(6):e0198809. doi: 10.1371/journal.pone.0198809. eCollection 2018.

18.

Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study.

Mukherjee S, Ibrahimi S, Machiorlatti M, Roman D, Saleem R, Hassan A, Baxley A, Vesely S, Aljumaily R.

Am J Ther. 2018 Nov/Dec;25(6):e767-e768. doi: 10.1097/MJT.0000000000000774. No abstract available.

PMID:
29746291
19.

Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study.

Mukherjee S, Ibrahimi S, Khalid B, Roman D, Zhao D, Aljumaily R.

J Oncol Pharm Pract. 2019 Apr;25(3):762-764. doi: 10.1177/1078155218771152. Epub 2018 Apr 24. No abstract available.

PMID:
29690815
20.

Switching the Smoothened Inhibitor May Have Benefit in Advanced Basal Cell Carcinoma.

Khalid B, Mukherjee S, Ibrahimi S, Cannon T, Gilles E, Moreau A, Razaq M.

Am J Ther. 2018 May/Jun;25(3):e394-e396. doi: 10.1097/MJT.0000000000000721. No abstract available.

PMID:
29557803

Supplemental Content

Loading ...
Support Center